Genentech vice presidents Vishva Dixit, M.D., Man-Wah Tan, Ph.D., and Todd McDevitt, Ph.D., are among the casualties in another round of layoffs at the South San Francisco subsidiary of Roche.
The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group, a company spokesperson said in an email. Genentech did not reveal how many positions are affected, but the spokesperson said that “targeted adjustments” are being made to “ensure our capabilities and investments are aligned with our core therapeutic areas and portfolio priorities.”
The layoffs were first reported by Endpoints News, which cited an internal communication stating that Genentech was shutting down its physiological chemistry and infectious disease teams and reducing staff in other groups. The publication cited an email sent by Aviv Regev, Ph.D., the head of the gRED group.
Dixit, who has served at Genentech for 29 years, headed up the physiological chemistry unit. Tan, who has been at the company for 16 years, leads the infectious disease group, while McDevitt has been the chief of the cell therapy unit for the last three years.
“We are deeply grateful for their leadership, groundbreaking discoveries, and the impact of their work,” Genentech’s spokesperson said.
